Clinical Virology Symposium 2022
Watch the Video and Meet Our Team
Aptima® CMV Quant Assay:
Insights from 3 Performance Studies
Industry and Science Workshop
Speakers:
Get a Deeper Dive into the Data with Poster Presentations
- PERFORMANCE EVALUATION OF A CMV QUANT ASSAY FOR THE DETECTION AND QUANTITATION OF CMV (CYTOMEGALOVIRUS) IN PLASMA SAMPLES 1,2S.S. Sam, 2R. Rogers, 3J. Ingersoll, 3C.S. Kraft, and 2A.M. Caliendo 1Division of Infectious Diseases, The Miriam Hospital, Providence, RI; 2Division of Infectious Diseases, Warren Alpert School of Medicine, Brown University, Providence, RI; 3Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 1P.M. Thwe and 1P. Ren 1Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555
- ANALYTICAL AND CLINICAL PERFORMANCE EVALUATION OF A CMV QUANT ASSAY USING PLASMA AND NON-PLASMA SAMPLES. 1V. Healer, 1L. Ferguson, 1A. Lima, 2K. Harrington and 1S. Silbert 1Department of Esoteric Testing/R&D, Tampa General Hospital, Tampa, FL, 2Scientific Affairs, Hologic, Inc., San Diego, CA
- CLINICAL PERFORMANCE EVALUATION OF THE APTIMA VIRAL ASSAYS FOR THE DETECTION AND QUANTITATION OF HIV-1, HCV, AND HBV IN PLASMA SAMPLES. 1S. Lewis, 2E. Morehead, 2H. Cheung, 3Karen Harrington, 1H.H. Mostafa 1Johns Hopkins School of Medicine, Department of Pathology, Division of Medical Microbiology, Johns Hopkins School of Medicine, Baltimore, MD, USA, 2Johns Hopkins Hospital, Department of Pathology, Division of Medical Microbiology, Baltimore, MD, USA, 3Scientific Affairs, Hologic, Inc., San Diego, CA
- PERFORMANCE EVALUATION OF THE APTIMA CMV QUANT ASSAY RUN ON THE AUTOMATED PANTHER PLATFORM FOR VIRAL LOAD MONITORING USING PLASMA FROM ORGAN TRANSPLANT PATIENTS. 1S.V. Nair, 1Y. Kang, 1A. Trieu, 1J. Fortunko, 1A. Warlock 1Hologic, Inc, San Diego, CA
- RNA ISOLATION FROM APTIMA SPECIMEN TRANSPORT MEDIUM FOR DOWNSTREAM PROCESSES 1R. Skvoretz, 1A. Worlock, 1M. Walcher 1Hologic, Inc., San Diego, CA, USA
- EVALUATION OF QUANTITATIVE REAL-TIME PCR FOR BK VIRUS (BKV) ON THE PANTHER FUSION SYSTEM WITH HOLOGIC BKV ASR. 1P.M. Thwe and P. Ren.1Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555
Aptima CMV Quant Assay is Now FDA Approved!
- Deliver accurate, consistent, and clinically-actionable viral load insights to post-transplant patients and their care teams
- Implement an efficient and cost-saving workflow on the Panther® system, our highly streamlined sample-to-result platform
- Ensure the highest degree of standardization necessary to reliably monitor viral load trends over time
At this year’s CVS conference in West Palm Beach, we took the opportunity to show you our fully-automated Panther system, the foundation of Panther® Scalable Solutions.
It was a pleasure to discuss in person how Panther Scalable Solutions can help streamline your lab's workflow and customize molecular diagnostic testing. With the Panther system you can choose from a broad assay menu and a suite of instrument add-ons, providing an economical and scalable path to your laboratory’s growth.
Discover how Panther Scalable Solutions can meet your needs in molecular diagnostic testing and expand your team´s productivity by reducing complexities and decreasing turnaround time.
19
Assays available
7
More in development
1
Scalable Platform
Learn about menu consolidation in molecular testing!
The Aptima CMV Quant assay is expanding Hologic’s virology portfolio. With a menu of 19 assays and an ever-growing pipeline of world-class assays, you can consolidate your molecular testing today and meet your lab’s growing needs tomorrow.
Assay Menu
Women's Health
Infectious Disease
EBV†
BKV†
SARS-CoV-2Flu/A/B/RSV†
GI Bacterial†
GI Extended Bacterial†
GI Viral†
GI Parasite†
Disclaimer:
*The Aptima SARS-CoV-2, Aptima Zika Virus, Aptima SARS-CoV-2/Flu and Panther Fusion SARS-CoV-2 assays have not been FDA cleared or approved: These tests have been authorized by FDA under an EUA for use by authorized laboratories; The Aptima and Panther Fusion SARS-CoV-2 assays have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; The Aptima Zika Virus assay has been authorized only for the detection of nucleic acid from Zika virus, not for any other viruses or pathogens; The Aptima SARS-CoV-2/ Flu assay has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2, Flu A, Flu B and not for any other viruses or pathogens. The Aptima SARS-CoV-2, Panther Fusion SARS-CoV-2, and Aptima SARS-CoV-2/Flu assays are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/ or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. The Aptima Zika assay is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection of Zika virus and/or diagnosis of Zika virus infection under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
†In development and not for sale.